Rapid and progressive CD4+ decline in a monkey infected with an SIV+HIV-1 chimeric virus. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Rapid and progressive CD4+ decline in a monkey infected with an SIV+HIV-1 chimeric virus.

J Vet Med Sci. 1998 Mar;60(3):361-3. Unique Identifier : AIDSLINE MED/98221558
Nagamachi D; Igarashi T; Shimada T; Kuwata T; Ui M; Ami Y; Enose Y; Ido E; Fukumoto M; Hayami M; Department of Pathology and Tumor Biology, Graduate School of; Medicine, Kyoto, Japan.

Abstract: We previously constructed a simian immunodeficiency virus+human immunodeficiency virus type 1 (HIV-1) chimeric virus, NM-3rN to generate a pathogenic HIV-1 in macaque monkeys. During the in vivo passage of this virus in several monkeys, a viral strain, R43-56 was obtained which acquired a better replication ability in vivo. MM121, one of the three monkeys inoculated with the R43-56, showed weight loss, diarrhea and a rapid and continuous decrease in CD4+ lymphocytes at the moribund stage. An autopsy revealed generalized lymphadenopathy, dehydration, and ileocecal intussusception. In situ hybridization showed that the virus infection was in systemic lymphoid organs. We are presently monitoring the survivors to obtain candidates for a more virulent virus. R43-56 may be a better challenge virus and useful tool for human acquired immunodeficiency syndrome research.
Keywords: *Acquired Immunodeficiency Syndrome/IMMUNOLOGY *CD4 Lymphocyte Count *HIV-1/PATHOGENICITY *Simian Acquired Immunodeficiency Syndrome/IMMUNOLOGY *SIV/PATHOGENICITYKWDacquiredimmunodeficiencysyndrome/immunologyKWDcd4lymphocytecountKWDhiv-1/pathogenicityKWDsimianacquiredimmunodeficiencysyndrome/immunologyKWDsiv/pathogenicity
980830
M9881182

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .